Travere therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Travere therapeutics Contact Number

Contact Travere Therapeutics Travere Therapeutics

1 hours ago Travere.com Show details

877-659-5518To report suspected adverse reactions, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or

1. 3611 Valley Centre Dr Ste 300, San Diego, CA 92130

Category: Contact SupportShow more

Travere Therapeutics

Just Now Travere.com Show details

SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being …

Estimated Reading Time: 3 mins

Category: Contact NumberShow more

Travere Therapeutics, Inc. Company Profile San Diego, …

8 hours ago Dnb.com Show details

(888) 969-7879Travere Therapeutics, Inc. is located in San Diego, CA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Travere Therapeutics, Inc. has 262 total employees across all of its locations and generates $198.32 million in sales (USD). There are 4 companies in the Travere Therapeutics, Inc. corporate family.

Employees: 135
Phone: (888) 969-7879
Location: 3611 Valley Centre Dr Ste 300, San Diego, 92130-3331, CA

Category: Contact NumberShow more

Travere Therapeutics Crunchbase Company Profile & …

9 hours ago Crunchbase.com Show details

(646) 564-3680Last Funding Type Post-IPO Equity. Also Known As Retrophin. Legal Name Travere Therapeutics, Inc. Stock Symbol NASDAQ:RTRX. Company Type For Profit. Contact Email [email protected]travere.com. Phone Number (646) 564-3680. Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring

Founded: 2011

Category: Contact NumberShow more

Travere Therapeutics, Inc.

9 hours ago Traveretherapeuticsinc.com Show details

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD).

Category: Contact NumberShow more

Travere Therapeutics Overview, News & Competitors

1 hours ago Zoominfo.com Show details

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 74,900 shares of its common stock to eleven new employees, …

Category: Contact NumberShow more

About Us Travere Therapeutics

9 hours ago Travere.com Show details

SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently …

Category: Contact NumberShow more

Study of Sparsentan Treatment in Pediatrics With

7 hours ago Clinicaltrials.gov Show details

877-659-5518You have reached the maximum number of saved studies (100). Contact: Travere Call Center: 1-877-659-5518: [email protected]travere.com: Locations. Layout table for location information; United States, Florida: Travere Investigational Site: Travere Therapeutics, Inc. More Information. Go to

Category: Contact NumberShow more

Travere Therapeutics Announces Positive Topline Interim

1 hours ago Ir.travere.com Show details

(855) 219-9219Travere Therapeutics will host a conference call and webcast today, Monday, August 16, 2021, at 8:30 a.m. ET to discuss the study results. To participate in the conference call, dial +1 (855) 219-9219 ( U.S. ) or +1 (315) 625-6891 (International), …

Category: Contact NumberShow more

Noah L. Rosenberg, M.D., Chief Travere Therapeutics

9 hours ago Travere.com Show details

Noah Rosenberg, M.D., has served as chief medical officer of Travere Therapeutics, Inc. since July 2018 and is responsible for overseeing the company's clinical development, as well as clinical operations, pharmacokinetics, medical affairs, patient advocacy and pharmacovigilance.

Category: Contact NumberShow more

Travere Therapeutics Company Profile Office Locations

7 hours ago Craft.co Show details

Travere Therapeutics has 239 employees across 2 locations and $198.32 M in annual revenue in FY 2020. See insights on Travere Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Travere Therapeutics Reports Third Quarter 2021 Financial

5 hours ago Ir.travere.com Show details

(855) 219-9219Travere Therapeutics will host a conference call and webcast today, Thursday, October 28, 2021 at 4:30 p.m. ET to discuss company updates as well as third quarter 2021 financial results. To participate in the conference call, dial +1 (855) 219-9219 ( U.S. ) or +1 (315) 625-6891 (International), confirmation code 5068414 shortly before 4:30 p.m

Category: Contact NumberShow more

Corporate Privacy Policy Travere Therapeutics

3 hours ago Travere.com Show details

888-969-7879We are Travere Therapeutics, Inc., and you can contact us via mail at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130, Attn: Chief Compliance Officer, via email at [email protected]travere.com, or you can call us at +1-888-969-7879.

Category: Contact NumberShow more

Vifor Pharma and Travere Therapeutics announce licensing

7 hours ago Businesswire.com Show details

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the compa

Category: Contact NumberShow more

Travere Therapeutics Reports First Quarter 2021 Financial

5 hours ago Ir.travere.com Show details

800-773-2954Travere Therapeutics will host a conference call and webcast today, Thursday, May 6, 2021 at 4:30 p.m. ET to discuss company updates as well as first quarter 2021 financial results. To participate in the conference call, dial +1-800-773-2954 ( U.S. ) or +1-847-413-3731 (International), confirmation code 50155370 shortly before 4:30 p.m. ET .

Category: Contact NumberShow more

Travere Therapeutics, Inc. (TVTX) 10K Annual Reports & 10Q

6 hours ago Last10k.com Show details

The following information was filed by Travere Therapeutics, Inc. (TVTX) on Wednesday, February 10, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the

Category: Contact NumberShow more

Travere Therapeutics to Present at Upcoming Investor

7 hours ago Nz.news.yahoo.com Show details

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that management will present a Company overview at the following upcoming virtual investor conferences in November: Jefferies 2021 London Healthcare ConferenceDate: Thursday, November 18, 2021Time: On-demand webcast available beginning 8:00 a.m. GMT (3:00 …

Category: Contact NumberShow more

Travere Therapeutics Funding, Financials, Valuation

8 hours ago Crunchbase.com Show details

Travere Therapeutics has raised a total of $317.5M in funding over 4 rounds. Their latest funding was raised on Feb 10, 2021 from a Post-IPO Equity round. Travere Therapeutics is registered under the ticker NASDAQ:RTRX . Travere Therapeutics is funded by Athyrium Capital Management, LP. Travere Therapeutics has invested in Perlara on Jul 31, 2014.

Category: Contact NumberShow more

Investor FAQs Travere Therapeutics, Inc.

6 hours ago Ir.travere.com Show details

Travere Therapeutics is a biopharmaceutical company with a global team dedicated to working with the rare disease community to identify, develop and deliver life-changing therapies. Travere Therapeutics’ CUSIP number is 89422G107. Where is Travere Therapeutics' headquarters located? How can I contact Travere Therapeutics or direct

Category: Contact NumberShow more

Do Hedge Funds Love Travere Therapeutics, Inc. (TVTX

2 hours ago Insidermonkey.com Show details

Travere Therapeutics, Inc. (NASDAQ:TVTX) was in 25 hedge funds’ portfolios at the end of the second quarter of 2021. The all time high for this statistic is 27. The all time high for this

Category: Contact NumberShow more

Travere Therapeutics to Report First Quarter 2021

2 hours ago Ir.travere.com Show details

(855) 859-2056The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 50155370. About Travere Therapeutics. At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a

Category: Contact NumberShow more

Jobs with Travere Therapeutics biospace.com

2 hours ago Biospace.com Show details

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Category: Contact NumberShow more

Travere Therapeutics Number of Employees 20122021 TVTX

7 hours ago Macrotrends.net Show details

Travere Therapeutics number of employees from 2012 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing

Category: Contact NumberShow more

Working at Travere Therapeutics Glassdoor

9 hours ago Glassdoor.com Show details

Glassdoor gives you an inside look at what it's like to work at Travere Therapeutics, including salaries, reviews, office photos, and more. This is the Travere Therapeutics company profile. All content is posted anonymously by employees working at Travere Therapeutics.

Category: Contact NumberShow more

Zacks: Brokerages Expect Travere Therapeutics, Inc

1 hours ago Marketbeat.com Show details

Equities research analysts predict that Travere Therapeutics, Inc. (NASDAQ:TVTX) will post sales of $54.83 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Travere Therapeutics' earnings. The highest sales estimate is …

Category: Contact NumberShow more

Do Hedge Funds Love Travere Therapeutics, Inc. (TVTX)?

3 hours ago Finance.yahoo.com Show details

Travere Therapeutics, Inc. (NASDAQ: TVTX) was in 25 hedge funds' portfolios at the end of the second quarter of 2021. The all time high for this statistic is …

Category: Contact NumberShow more

Travere Therapeutics, Inc. to Host Earnings Call

4 hours ago Finance.yahoo.com Show details

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Travere Therapeutics, Inc. (NASDAQ:TVTX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at

Category: Contact NumberShow more

Travere Therapeutics Reports Third Quarter 2021 Financial

8 hours ago Finance.yahoo.com Show details

Travere Therapeutics will host a conference call and webcast today, Thursday, October 28, 2021 at 4:30 p.m. ET to discuss company updates as well as third quarter 2021 financial results.

Category: Contact NumberShow more

Travere Therapeutics and Vifor Pharma Announce Licensing

8 hours ago Finance.yahoo.com Show details

SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint

Category: Contact NumberShow more

Quarterly Report (Form 10Q) MarketScreener

8 hours ago Marketscreener.com Show details

The number of shares of outstanding common stock, par value $0.0001 per share, of the Registrant as of October 26, 2021 was 61,226,392. Table of Contents TRAVERE THERAPEUTICS, INC.

Category: Contact NumberShow more

Travere Therapeutics to Report Third Quarter 2021 Financial

9 hours ago Globenewswire.com Show details

SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the

Category: Contact NumberShow more

Travere Therapeutics, Inc. (TVTX) Latest Stock News

2 hours ago Finance.yahoo.com Show details

Travere Therapeutics, Inc. Analyst Report: Merck & Co., Inc. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease

Category: Contact NumberShow more

Travere Therapeutics Reports Third Quarter 2021 Financial

5 hours ago Marketscreener.com Show details

(855) 219-9219Travere Therapeutics will host a conference call and webcast today, Thursday, October 28, 2021 at 4:30 p.m. ET to discuss company updates as well as third quarter 2021 financial results. To participate in the conference call, dial +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International), confirmation code 5068414 shortly before 4:30 p.m. ET.

Category: Contact NumberShow more

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q3 2021

8 hours ago Seekingalpha.com Show details

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2021 Earnings Conference Call October 28, 2021 04:30 PM ET Company Participants Chris Cline - …

Category: Contact NumberShow more

Vifor Pharma and Travere Therapeutics announce licensing

6 hours ago Viforpharma.com Show details

888-969-7879Travere Therapeutics: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications +1 888-969-7879 [email protected]travere.com. About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies.

Category: Contact NumberShow more

IgA Nephropathy (IgAN) Market Trends and Epidemiology 2018

3 hours ago Finanzen.net Show details

The total number of prevalent cases of IgA Nephropathy associated in 7MM countries was 377,829 in 2020. Travere Therapeutics Inc. Sparsentan is a …

Category: Contact NumberShow more

Peter Heerma Net Worth, Biography & Insider Trading History

4 hours ago Insidertrades.com Show details

(888) 969-7879The corporate mailing address for Mr. Heerma and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]

Category: Contact NumberShow more

Travere Therapeutics Tech Stack, Apps, Patents & Trademarks

Just Now Crunchbase.com Show details

Travere Therapeutics uses 26 technology products and services including Google Analytics , Google Fonts , and Vimeo, according to G2 Stack. Travere Therapeutics is actively using 35 technologies for its website, according to BuiltWith. These include LetsEncrypt , Apple Mobile Web Clips Icon , and WordPress.

Category: Tech SupportShow more

Travere Therapeutics Inc. (NASDAQ:TVTX) Is 7.27% Higher

5 hours ago Marketingsentinel.com Show details

Travere Therapeutics Inc.’s shares saw a change of -3.58% in year-to-date performance and have moved 7.27% in past 5-day. Travere Therapeutics Inc. (NASDAQ:TVTX) showed a performance of 4.99% in past 30-days. Number of shares sold short was 6.92 million shares which calculate 2.87 days to cover the short interests.

Category: Contact NumberShow more

IgA Nephropathy (IgAN): Global Market Insights

6 hours ago Bdtonline.com Show details

The total number of prevalent cases of IgA Nephropathy associated in 7MM countries was 377,829 in 2020. Travere Therapeutics Inc. Sparsentan is a …

Category: Contact NumberShow more

Gerry Lin's email & phone number Director, Total Rewards

8 hours ago Signalhire.com Show details

View Gerry Lin's email address: [email protected]travere.com & phone: +1-205-xxx-xx78's profile as Director, Total Rewards at Travere Therapeutics, located in San Diego County, California. Find contacts: direct phone number, email address, work experience.

Category: Phone NumberShow more

Travere Therapeutics to Report Second Quarter 2021

Just Now Globenewswire.com Show details

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the

Category: Contact NumberShow more

Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected to

7 hours ago Marketbeat.com Show details

Equities analysts predict that Travere Therapeutics, Inc. (NASDAQ:TVTX) will report earnings of ($0.72) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Travere Therapeutics' earnings, with the lowest EPS estimate coming in at ($0.88) and the highest estimate coming in at ($0.56).

Category: Contact NumberShow more

5 Best Biotech Stocks to Buy According to Joseph Edelman’s

2 hours ago Insidermonkey.com Show details

Number of Hedge Fund Holders: 25 Travere Therapeutics, Inc. (NASDAQ: TVTX) is a California-based company engaged in the discovery and production of …

Category: Tech SupportShow more

Travere Therapeutics and Vifor Pharma Announce Licensing

8 hours ago Morningstar.com Show details

Contact: Travere Therapeutics: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications

Category: Contact NumberShow more

Vifor Pharma and Travere Therapeutics announce licensing

3 hours ago Benzinga.com Show details

Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the companies have entered into a joint collaboration and …

Category: Contact NumberShow more

TVTX Stock Price Travere Therapeutics Inc. Stock Quote

8 hours ago Marketwatch.com Show details

Travere Therapeutics stock price target cut to $23 from $30 at Evercore ISI. May. 26, 2021 at 6:26 a.m. ET by Tomi Kilgore.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Who are Travere Therapeutics and what are they doing?

SAN DIEGO, August 16, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).

When does Travere Therapeutics report second quarter results?

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2021 financial results and provided a corporate update. Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease.

Who is the CEO of Travere health plan?

Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations.

Popular Brands

Tsmc
Tesla
Tata
Toyota
Tesco
Tgs
Tui